BCRX

9.74

1.91% -0.19

Dopo l'orario di chiusura: 9.74

Biocryst Pharmaceuticals Inc (BCRX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BCRX Giù? Forum Previsione

Precedente Chiudi:

$9.93

Aprire:

$9.94

Volume 24 ore:

2.88M

Relative Volume:

0.67

Capitalizzazione di mercato:

$2.30B

Reddito:

$503.49M

Utile/perdita netta:

$-53.47M

Rapporto P/E:

-37.46

EPS:

-0.26

Flusso di cassa netto:

$-26.89M

1 W Prestazione:

-2.21%

1M Prestazione:

-8.03%

6M Prestazione:

+26.99%

1 anno Prestazione:

+60.20%

Intervallo 1D:

$9.67

$10.02

Intervallo di 1 settimana:

$9.67

$10.15

Portata 52W:

$6.00

$11.31

Biocryst Pharmaceuticals Inc Stock (BCRX) Company Profile

Nome

Biocryst Pharmaceuticals Inc

Settore

Healthcare (1170)

Industria

Drug Manufacturers - Specialty & Generic (84)

Telefono

919-859-1302

Indirizzo

4505 EMPEROR BOULEVARD, DURHAM, NC

Dipendente

580

Cinguettio

@biocrystpharma

Prossima data di guadagno

2025-02-24

Ultimi documenti SEC

BCRX's Discussions on Twitter

Confronta BCRX con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BCRX Biocryst Pharmaceuticals Inc	9.74	2.30B	503.49M	-53.47M	-26.89M	-0.26
RGC Regencell Bioscience Holdings Ltd	21.73	303.95B	0	-5.87M	-767.30K	-0.45
ZTS Zoetis Inc	157.23	74.39B	9.29B	2.52B	2.28B	5.57
HLN Haleon Plc Adr	10.50	48.97B	14.35B	1.85B	0	0.4023
TAK Takeda Pharmaceutical Co Adr	14.97	47.39B	30.08B	710.16M	4.45B	0.2182
TEVA Teva Pharmaceutical Industries Ltd Adr	17.00	20.17B	16.54B	-1.64B	749.00M	-1.45

Biocryst Pharmaceuticals Inc Stock (BCRX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-04-29	Iniziato	Cantor Fitzgerald	Overweight
2025-02-25	Iniziato	Wedbush	Outperform
2023-11-20	Ripresa	JP Morgan	Overweight
2023-09-18	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2023-08-04	Aggiornamento	Jefferies	Hold → Buy
2023-07-13	Aggiornamento	BofA Securities	Neutral → Buy
2023-02-22	Aggiornamento	Needham	Hold → Buy
2022-11-02	Aggiornamento	Evercore ISI	In-line → Outperform
2022-08-05	Downgrade	Evercore ISI	Outperform → In-line
2022-08-05	Downgrade	Oppenheimer	Outperform → Perform
2022-04-18	Downgrade	Barclays	Overweight → Equal Weight
2022-04-11	Downgrade	BofA Securities	Buy → Neutral
2021-12-10	Iniziato	Oppenheimer	Outperform
2021-08-06	Downgrade	Jefferies	Buy → Hold
2021-08-03	Iniziato	Cantor Fitzgerald	Overweight
2021-03-01	Iniziato	Cowen	Outperform
2020-09-29	Ripresa	JP Morgan	Overweight
2020-06-17	Iniziato	BTIG Research	Neutral
2020-05-05	Aggiornamento	Barclays	Equal Weight → Overweight
2019-11-15	Aggiornamento	BofA/Merrill	Neutral → Buy
2019-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-11-16	Ripresa	Piper Jaffray	Overweight
2018-08-08	Ripresa	JP Morgan	Overweight
2018-07-17	Aggiornamento	BofA/Merrill	Underperform → Neutral
2018-06-22	Iniziato	Seaport Global Securities	Neutral
2018-01-02	Aggiornamento	RBC Capital Mkts	Sector Perform → Outperform
2017-12-20	Iniziato	Barclays	Equal Weight
2017-09-15	Iniziato	RBC Capital Mkts	Sector Perform
2017-09-06	Aggiornamento	JP Morgan	Neutral → Overweight
2017-09-06	Aggiornamento	Jefferies	Hold → Buy
2017-02-16	Iniziato	Ladenburg Thalmann	Buy
2016-08-12	Aggiornamento	Piper Jaffray	Neutral → Overweight
2016-08-04	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
2016-02-09	Reiterato	FBR Capital	Outperform
2016-02-09	Downgrade	JP Morgan	Overweight → Neutral
2016-02-09	Downgrade	Needham	Buy → Hold

Mostra tutto

Biocryst Pharmaceuticals Inc Borsa (BCRX) Ultime notizie

Jun 18, 2025

Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? - Nasdaq

Jun 18, 2025

Jun 16, 2025

BioCryst Stockholders Approve Stock Incentive Plan Amendment - TipRanks

Jun 16, 2025

BioCryst reports long-term efficacy of ORLADEYO in HAE treatment By Investing.com - Investing.com South Africa

Jun 16, 2025

Orladeyo approved in Colombia to prevent HAE swelling attacks - Angioedema News

Jun 16, 2025

BioCryst reports long-term efficacy of ORLADEYO in HAE treatment - Investing.com Australia

Jun 16, 2025

BioCryst (BCRX) Showcases Promising Results for ORLADEYO in HAE Treatment | BCRX Stock News - GuruFocus

Jun 16, 2025

BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO® (berotralstat) Across all Ages at EAACI | BCRX Stock News - GuruFocus

Jun 16, 2025

BioCryst Presents New Data on the Long-term Efficacy and - GlobeNewswire

Jun 16, 2025

ORLADEYO Clinical Trial Results: 86% Attack Reduction Transforms Life for HAE Patients of All Ages - Stock Titan

Jun 16, 2025

Jun 13, 2025

Sector Update: Health Care Stocks Lean Lower Premarket Friday - MarketScreener

Jun 13, 2025

BioCryst Pharmaceuticals, Inc. Announces National Institute of Drug and Food Surveillance Grants Approval for Oral, Once-Daily ORLADEYO - marketscreener.com

Jun 13, 2025

Colombia approves BioCryst’s oral HAE treatment ORLADEYO By Investing.com - Investing.com Canada

Jun 13, 2025

BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Preventio - GuruFocus

Jun 13, 2025

BioCryst Pharmaceuticals Receives Approval for Orladeyo in Colombia - marketscreener.com

Jun 13, 2025

BCRX: BioCryst's ORLADEYO Approved in Colombia for HAE Prevention | BCRX Stock News - GuruFocus

Jun 13, 2025